Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. 

Spiriva Respimat is a long-acting muscarinic antagonist (LAMA), making it the first new class of inhalation agents approved for asthma in over 10 years. Spiriva Respimat is steroid-free and has a different mechanism of action than a long-acting beta-2 agonist (LABA). Tiotropium has similar affinity to the subtypes of muscarinic receptors, M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3-receptors at the smooth muscle leading to bronchodilation.

RELATED: Asthma Med Use During Pregnancy Linked to Increased Autism Risk

The expanded approval for Spiriva Respimat was based on efficacy and safety data from a comprehensive clinical trial program, which included 12 trials of approximately 5,000 patients with mild, moderate, and severe symptomatic asthma on at least an inhaled corticosteroid (ICS) or ICS/LABA.

Spiriva Respimat is already indicated for the the long-term maintenance treatment of bronchospasm due to chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema—to reduce exacerbations of COPD. The 1.25mcg/actuation strength is intended for this new indication.

It is available as 1.25mcg/actuation and 2.5mcg/actuation dosage strengths containing a total of 60 metered actuations. Spiriva Respimat is supplied in a carton containing one Spiriva Respimat cartridge and one inhaler.

For more information call (800) 542-6257 or visit Spiriva.com.